8. Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries (motions for resolutions tabled)

Council and Commission statements: Meeting the Global COVID-19 challenge: effects of waiver of the WTO TRIPS agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries (2021/2692(RSP))

The debate had taken place on 19 May 2021 (minutes of 19.5.2021, item 3).

Motions for resolutions to wind up the debate tabled under Rule 132(2):

- Iratxe García Pérez, Kathleen Van Brempt, Marek Belka and Heléne Fritzon, on behalf of the S&D Group, on meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries (2021/2692(RSP)) (B9-0306/2021);

- Sara Matthieu, on behalf of the Verts/ALE Group, on meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries (2021/2692(RSP)) (B9-0307/2021);

- Helmut Scholz, Manon Aubry, Martin Schirdewan, Marc Botenga, Kateřina Konečná, Dimitrios Papadimoulis, Marisa Matias, Silvia Modig, Nikolaj Villumsen, João Ferreira, Malin Björk, Manuel Bompard, Idoia Villanueva Ruiz, Sira Rego, Miguel Urbán Crespo, Pernando Barrena Arza, Mick Wallace and Chris MacManus, on behalf of The Left Group, on meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries (2021/2692(RSP)) (B9-0308/2021);

- Sven Simon, Christophe Hansen, Peter Liese, Christian Ehler, Angelika Niebler and Tomas Tobé, on behalf of the PPE Group, on meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries (2021/2692(RSP)) (B9-0309/2021);

- Michiel Hoogeveen, Geert Bourgeois and Jan Zahradil, on behalf of the ECR Group, on meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries (2021/2692(RSP)) (B9-0310/2021);

- Samira Rafaela, Karen Melchior, Dita Charanzová, Liesje Schreinemacher, Svenja Hahn, Nicola Danti, Nicolae Ştefănuță, Frédérique Ries, Petras Auštrevičius and Martin Hojsík, on behalf of the Renew Group, on meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries (2021/2692(RSP)) (B9-0311/2021).

Vote: minutes of 9.6.2021, item 9 (amendments); minutes of 9.6.2021, item 19 (final vote).

Announcement of voting results: minutes of 9.6.2021, item 16 (amendments); minutes of 10.6.2021, item 2 (final vote).